Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Qiagen NV
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
It has taken a while but European regulators have finally followed their US counterparts and approved Piqray, making it the first targeted medicine for HR+/HER2- advanced breast cancer with a PIK3CA mutation.
Medtech industry group AdvaMed has developed a registry to share data on how many COVID-19 diagnostic tests are available and where they are, with a goal of foreseeing and nipping in the bud potential test shortages. Thirteen diagnostic manufacturers – including Abbott, Roche, Siemens and Thermo Fisher Scientific – have partnered with AdvaMed on the initiative.
Hedge fund Davidson Kempner advised Qiagen to ask for a higher acquisition price from Thermo Fisher Sciences as COVID-19 has increased demand for diagnostic products.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Amnisure International LLC
- Biobase, Biotage
- Corbett Life Science Pty. Ltd.
- Digene Corporation
- eGene, Inc.
- ESE GmbH
- Ingenuity Systems Inc
- Genaco Biomedical Products, Inc.
- MO BIO Laboratories
- OmicSoft Corporation
- SABiosciences Corporation
- Ipsogen S.A.
- Qiagen Manchester Limited
- Qiagen N.V.
- Xeragon Inc.